Pembrolizumab versus paclitaxel in gastro-oesophageal adenocarcinoma

Mené dans 30 pays sur 395 patients atteints d'un cancer de l'estomac ou de la jonction œsogastrique de stade avancé et surexprimant PD-L1 , cet essai de phase III compare l'efficacité, du point de vue de la survie globale et de la survie sans progression, et la toxicité du pembrolizumab et du paclitaxel, après l'échec d'une chimiothérapie de première ligne à base de sels de platine et de fluoropyrimidine

Résumé en anglais

Immune checkpoint blockade has altered the treatment landscape for many cancers. In the first wave of immunotherapy approvals, studies showed that patients with highly immunogenic tumours such as malignant melanoma gained substantial survival benefits from treatment with anti-CTLA-4 or anti-PD-1 antibodies.1,2 These early wins have given way to mixed evidence for immunotherapy for tumours on the margin of immune exclusion, such as gastro-oesophageal adenocarcinoma. Anti-PD-1 therapy has been shown to be associated with modest response rates and an improvement in overall survival in chemorefractory gastro-oesophageal cancer.